Avrobio (NASDAQ:AVRO) Earns Buy Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of Avrobio (NASDAQ:AVRO) in a research report released on Tuesday, TipRanks reports. They currently have a $35.00 target price on the stock.
Several other analysts have also issued reports on the stock. Janney Montgomery Scott restated a buy rating on shares of Avrobio in a report on Friday, November 8th. ValuEngine lowered shares of Avrobio from a hold rating to a sell rating in a report on Saturday, January 18th. Zacks Investment Research upgraded shares of Avrobio from a hold rating to a buy rating and set a $23.00 price objective on the stock in a report on Tuesday, February 4th. Nomura initiated coverage on shares of Avrobio in a report on Monday, October 28th. They issued a buy rating and a $35.00 price objective on the stock. Finally, Mizuho boosted their price objective on shares of Avrobio from to and gave the company a buy rating in a report on Tuesday. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. Avrobio has a consensus rating of Buy and a consensus price target of $33.63.
Shares of AVRO opened at $24.16 on Tuesday. The firm has a market cap of $728.34 million, a P/E ratio of -9.19 and a beta of 2.73. Avrobio has a 12-month low of $12.67 and a 12-month high of $29.32. The company’s 50-day moving average price is $21.51 and its 200 day moving average price is $18.30.
Several institutional investors have recently made changes to their positions in AVRO. Point72 Hong Kong Ltd acquired a new position in shares of Avrobio during the fourth quarter worth about $26,000. CWM LLC acquired a new position in shares of Avrobio during the third quarter worth about $28,000. Tower Research Capital LLC TRC acquired a new position in shares of Avrobio during the third quarter worth about $28,000. Great West Life Assurance Co. Can acquired a new position in shares of Avrobio during the fourth quarter worth about $28,000. Finally, Marshall Wace LLP acquired a new position in Avrobio in the fourth quarter valued at approximately $30,000. 77.99% of the stock is owned by institutional investors and hedge funds.
Avrobio Company Profile
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Read More: Asset Allocation, Balancing Your Investments
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.